

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan

Phone No. 011-47020100, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com CIN : L74999RJ1992PLC013387

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DEC., 2014

(Rs. IN LAKHS)

PART I	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2014 Unaudited	30.09.2014 Unaudited	31.12.2013 Unaudited	31.12.2014 Unaudited	31.12.2013 Unaudited	31.03.2014 Audited
1	INCOME FROM OPERATION						
	a) Net Sales / Income from Operation	830.41	1117.62	933.18	2835.36	2801.24	3913.35
	b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operation (Net)	830.41	1117.62	933.18	2835.36	2801.24	3913.35
2	EXPENDITURE						
	(a) Cost of Materials Consumed	486.42	737.26	586.67	1823.85	1867.58	2599.81
	(b) Changes in inventories of finished goods, work in progress and stock in trade	-60.30	4.40	-8.08	-89.77	-5.52	-5.52
	(c) Employees benefit Expenses	70.98	68.82	54.04	203.38	157.65	229.90
	(d) Depreciation & Amortisation Expenses	17.86	17.52	22.45	53.95	60.94	81.95
	(e) Other Expenditure	255.52	200.17	214.90	624.29	567.44	786.98
	Total Expenditure	770.48	1028.17	869.98	2615.70	2648.09	3693.12
3	Profit from Operation before Other Income, finance costs & Exceptional Items	59.93	89.45	63.20	219.66	153.15	220.23
4	Other Income	16.72	4.14	-0.11	28.02	28.91	38.18
5	Profit from ordinary activities before Finance Costs & Exceptional Items	76.65	93.59	63.09	247.68	182.06	258.41
6	Interest	15.31	26.37	4.32	63.37	9.77	23.57
7	Profit from Ordinary activities after Finance Costs but before Exceptional Items	61.34	67.22	58.77	184.31	172.29	234.84
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	11.46
9	Profit(+)/Loss(-) before Tax (-)	61.34	67.22	58.77	184.31	172.29	223.38
10	Tax Expenses						
	(a) Provision for Taxation	20.84	22.85	19.96	62.64	58.56	61.90
	(b) Provision for Deferred Tax	0.00	0.00	0.00	0.00	0.00	12.30
	Total Tax Expenses	20.84	22.85	19.96	62.64	58.56	74.20
11	Net Profit (+)/Loss(-) from Ordinary Activities after tax	40.50	44.37	38.81	121.67	113.73	149.18
12	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / Loss	40.50	44.37	38.81	121.67	113.73	149.18
14	Operating Profit Before Exceptional Items						
15	Paid-up Equity Share Capital	773.87	703.87	703.87	773.87	703.87	703.87
16	Reserve excluding Revaluation Reserve (as per Balance Sheet)	N.A.	N.A.	N.A.	N.A.	N.A.	830.13
17(I)	Earning Per Share (before extraordinary items) Basic & Diluted	0.52	0.63	0.65	1.57	1.80	2.12
17(II)	Earning Per Share (after extraordinary items) Basic & Diluted Annualised Basic EPS Before Extraordinary /exceptional items	0.52	0.63	0.65	1.57	1.80	2.12
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	3973701	3623701	3613522	3973701	3613522	3610371
	- Percentage of Shareholding	51.35	51.48	51.34	51.35	51.34	51.29
2	Promoters and promoter group shareholding						
	A) Pledged/Encumbered						
	-Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
	-Percentage of shares (as a % of the total shareholding of promoter & promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
	-Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
	B) Non-encumbered						
	-Number of shares	3764999	3414999	3425178	3764999	3425178	3428329
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	48.65	48.52	48.66	48.65	48.66	48.71
	-Percentage of shares (as a % of the total share capital of the company)	100.00	100.00	100	100.00	100	100
B	INVESTOR COMPLAINTS	Quarter Ended 31.12.2014					
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	NIL					
	Disposed off during the quarter	NIL					
	Remaining unresolved at the end of the quarter	NIL					

Notes:

- The above statement of financial results was taken on record by the Board of Directors at their meeting held on 29th Jan. 2015.
- A Limited review of the financial results of the quarter ended 31st Dec. 2014 has been carried out by the Statutory Auditors of the company pursuant to Clause 41 of the Listing Agreement.
- Previous period figures are regrouped/reclassified in line with the current period.
- The above Unaudited Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on 29th January, 2015. The Statutory Auditors have carried out a limited review of the above Financial Results.

For and on behalf of Board of Directors



Place : Delhi
Dated : 29.01.2015

DEEPIKA SETIA & CO.

CHARTERED ACCOUNTANTS

190, III Floor, Dr. Mukherjee Nagar,
Delhi-110009

Phone : 011-27604265, 5265

E-mail : setia15@vsnl.com

: deepika.setia@inbox.com

INDEPENDENT AUDITORS'REVIEW REPORT

TO THE BOARD OF DIRECTORS OF
"TITAN BIOTECH LIMITED"

1. We have reviewed the accompanying Statement of Unaudited Financial results of **TITAN BIOTECH LIMITED** ('the Company') for the Quarter and Nine Months ended **31st December, 2014** ('the Statement'), being submitted by the Company pursuant to the requirements of Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures in Part II-Select Information referred to in paragraph 4 below. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the financial Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with Accounting Standards specified under the Companies Act, 1956 (which are deemed to be applicable as per Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Further, we also report that we have traced the number of shares as well as the percentage of shareholding in respect of the aggregate amount of public shareholding and the number of shares as well as the percentage of shares pledged/encumbered and non-encumbered in respect of the aggregate amount of promoters and promoter group shareholding in terms of Clause 35 of the Listing Agreements with the Stock Exchanges and the particulars relating to investor complaints disclosed in Part II- Select Information for the Quarter and Nine Months Ended 31st December 2014 of the Statement, from the details furnished by the Registrars.

For Deepika Setia & Co

Chartered Accountants

FRN-013515N



D.S.Kajal
(D.S.Kajal)

Partner

M.No.091609

Delhi, 29th January 2015